Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received a 4-day suspension order for the drug license of a single store located at Market Road Varni Exp in Telangana. The order was issued by the Assistant Director, Drugs Control Administration, Nizamabad, under Rule 65 of the Drugs and Cosmetics Act, 1940, and was received on September 29, 2025. The company estimates a potential revenue loss of around Rs 0.77 lakh (about Rs 77,000) due to this suspension. The disclosure was made under SEBI Listing Regulations as a routine regulatory update.
The financial impact is negligible — a four-day suspension at one store out of Medplus's large network amounts to roughly Rs 77,000 in lost revenue, which is immaterial to overall operations. Shareholders are unlikely to see any meaningful effect on the stock or business.